Verdolini R, Simonacci F, Menon S, Pavlou P, Mannello B
Department of Dermatology, The Princess Alexandra Hospital, Harlow, Essex, UK -
G Ital Dermatol Venereol. 2015 Apr;150(2):155-62. Epub 2014 Jun 13.
Despite a better insight into its pathogenesis, hidradenitis suppurativa (HS) remains very frustrating to treat. Acitretin has been described as one of the agents with the highest effective profile. Acitretin however, due to its teratogenicity and prolonged half-life (up to three years) is not an option in young women of fertile age who, unfortunately, are the target of this disease. Alitretinoin has a similar pharmacology action to acitretin, but much shorter half-life (only four weeks), making it a far much more attractive option compared to acitretin for women of child-bearing age. The aim of this paper was to evaluate the use of alitretinoin in treating recalcitrant cases of HS, which have not been responsive to standard treatments.
Fourteen patients (all female, of child-bearing age), who persistently failed traditional treatments, were treated with alitretinoin 10 mg/day for 24 weeks. The disease trend was evaluated by using both Sartorius and Dermatology Life Quality Index scores at time 0, at week 12 and at week 24.
A significant improvement was recorded in 78.5% of the cases.
Although more studies are necessary, this preliminary study shows that alitretinoin may have a role in the treatment of HS specifically in women of fertile age.
尽管对化脓性汗腺炎（HS）的发病机制有了更深入的了解，但治疗起来仍然非常棘手。阿维A已被认为是疗效最佳的药物之一。然而，由于其致畸性和较长的半衰期（长达三年），对于育龄期年轻女性（不幸的是，她们是这种疾病的目标人群）来说，并非一种选择。阿利特维A与阿维A具有相似的药理作用，但半衰期短得多（仅四周），这使得它与阿维A相比，对育龄期女性更具吸引力。本文的目的是评估阿利特维A在治疗对标准治疗无反应的顽固性HS病例中的应用。
14名（均为育龄期女性）持续传统治疗失败的患者接受阿利特维A 10mg/天治疗24周。在第0周、第12周和第24周使用萨托里厄斯评分和皮肤病生活质量指数评分评估疾病趋势。
78.5%的病例有显著改善。
尽管还需要更多研究，但这项初步研究表明，阿利特维A可能在HS治疗中发挥作用，特别是对育龄期女性。
